RU2275373C2 - Макрогетероциклические соединения - Google Patents
Макрогетероциклические соединения Download PDFInfo
- Publication number
- RU2275373C2 RU2275373C2 RU2003120442/04A RU2003120442A RU2275373C2 RU 2275373 C2 RU2275373 C2 RU 2275373C2 RU 2003120442/04 A RU2003120442/04 A RU 2003120442/04A RU 2003120442 A RU2003120442 A RU 2003120442A RU 2275373 C2 RU2275373 C2 RU 2275373C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- alkyl
- mmol
- reaction mixture
- kinase
- Prior art date
Links
- 0 N=C(C(C(N1)=O)=C2C1=O)c1ccccc1[N+]**/N=C/CC[n]1c(cccc3)c3c2c1 Chemical compound N=C(C(C(N1)=O)=C2C1=O)c1ccccc1[N+]**/N=C/CC[n]1c(cccc3)c3c2c1 0.000 description 9
- FIHYVNNNXDBPSY-UHFFFAOYSA-N CCN(CCCCC[n]1c(nccc2)c2c(C(C(N2)=O)=C3C2=O)c1)CCCC[n]1c2ncccc2c3c1 Chemical compound CCN(CCCCC[n]1c(nccc2)c2c(C(C(N2)=O)=C3C2=O)c1)CCCC[n]1c2ncccc2c3c1 FIHYVNNNXDBPSY-UHFFFAOYSA-N 0.000 description 1
- AXQDHZOSYHAWPY-UHFFFAOYSA-N O=C(C(c1c[n](CCCCc2cccc(CCCC3)n2)c2c1cccn2)=C1c2c[n]3c3ncccc23)NC1=O Chemical compound O=C(C(c1c[n](CCCCc2cccc(CCCC3)n2)c2c1cccn2)=C1c2c[n]3c3ncccc23)NC1=O AXQDHZOSYHAWPY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25416100P | 2000-12-08 | 2000-12-08 | |
| US60/254,161 | 2000-12-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003120442A RU2003120442A (ru) | 2004-12-27 |
| RU2275373C2 true RU2275373C2 (ru) | 2006-04-27 |
Family
ID=22963161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003120442/04A RU2275373C2 (ru) | 2000-12-08 | 2001-12-06 | Макрогетероциклические соединения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6828327B2 (de) |
| EP (1) | EP1345946B1 (de) |
| JP (1) | JP2004526676A (de) |
| AT (1) | ATE301661T1 (de) |
| AU (2) | AU2737102A (de) |
| CA (1) | CA2431187A1 (de) |
| DE (1) | DE60112611T2 (de) |
| ES (1) | ES2245994T3 (de) |
| MX (1) | MXPA03005139A (de) |
| RU (1) | RU2275373C2 (de) |
| WO (1) | WO2002046197A1 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2518471C2 (ru) * | 2008-08-14 | 2014-06-10 | Тиботек Фармасьютикалз | Макроциклические индольные производные, применимые в качестве ингибиторов вируса гепатита с |
| RU2630958C2 (ru) * | 2015-12-29 | 2017-09-15 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) | Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения |
| RU2728579C2 (ru) * | 2015-07-21 | 2020-07-30 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы и их применение |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1312154C (zh) | 2002-03-05 | 2007-04-25 | 伊莱利利公司 | 作为激酶抑制剂的嘌呤衍生物 |
| IL163777A0 (en) | 2002-03-08 | 2005-12-18 | Lilly Co Eli | Kinase inhibitors |
| WO2003095452A1 (en) * | 2002-05-08 | 2003-11-20 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
| TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| US20090155266A1 (en) * | 2004-01-16 | 2009-06-18 | Yale University | Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases |
| CA2580224A1 (en) * | 2004-09-17 | 2006-03-30 | Henry Ford Health System | Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| CN101484575B (zh) | 2005-06-08 | 2013-10-02 | 森托科尔公司 | 用于眼变性的细胞疗法 |
| EP1940411A4 (de) * | 2005-09-29 | 2008-10-29 | Janssen Pharmaceutica Nv | Makroheterozyklische verbindungen als kinase-hemmer |
| US7759331B2 (en) * | 2006-03-10 | 2010-07-20 | Janssen Pharmaceutica Nv | Pyridine-containing macroheterococylic compounds as kinase inhibitors |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| KR20090100363A (ko) | 2006-12-19 | 2009-09-23 | 노파르티스 아게 | 키나제 억제제로서의 인돌릴말레이미드 유도체 |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| KR101617243B1 (ko) | 2007-07-31 | 2016-05-02 | 라이프스캔, 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| CA3123528C (en) | 2007-11-27 | 2026-01-13 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
| AU2008339917B2 (en) | 2007-12-24 | 2013-02-07 | Tibotec Pharmaceuticals | Macrocyclic indoles as hepatitis C virus inhibitors |
| BR122017025207B1 (pt) | 2008-02-21 | 2021-03-16 | Centocor Ortho Biotech Inc | superfície que faz parte de um recipiente ou matriz destinada para uso em uma cultura de células ou análises, desprovida de uma camada de células alimentadoras e desprovida de uma camada adsorvente |
| US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| US20100015711A1 (en) | 2008-06-30 | 2010-01-21 | Janet Davis | Differentiation of Pluripotent Stem Cells |
| CA2742267C (en) | 2008-10-31 | 2019-06-04 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| BRPI0919885A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
| US20100124781A1 (en) | 2008-11-20 | 2010-05-20 | Shelley Nelson | Pluripotent Stem Cell Culture on Micro-Carriers |
| AU2009316583B2 (en) | 2008-11-20 | 2016-04-21 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
| BR112012001480A2 (pt) | 2009-07-20 | 2015-09-01 | Janssen Biotech Inc | Diferenciação de células-tronco embriônicas humanas |
| JP5819826B2 (ja) | 2009-07-20 | 2015-11-24 | ヤンセン バイオテツク,インコーポレーテツド | ヒト胚性幹細胞の分化 |
| CA2768644A1 (en) | 2009-07-20 | 2011-01-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| EP2942060A1 (de) | 2009-09-29 | 2015-11-11 | Joslin Diabetes Center, Inc. | Verwendung von Proteinkinase-C-Delta (PKCD-)Hemmern zur Behandlung von Diabetes, Adipositas und Leberverfettung |
| CA2784415C (en) | 2009-12-23 | 2019-06-18 | Jean Xu | Differentiation of human embryonic stem cells |
| US9133439B2 (en) | 2009-12-23 | 2015-09-15 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| CN102207678B (zh) * | 2010-01-25 | 2015-05-20 | 罗门哈斯电子材料有限公司 | 包含含氮化合物的光致抗蚀剂 |
| JP5902103B2 (ja) * | 2010-02-22 | 2016-04-13 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | プロテインキナーゼcイプシロン(pkc−イプシロン)タンパク質レベルの、アルツハイマー病に特異的な変化 |
| WO2011109279A2 (en) | 2010-03-01 | 2011-09-09 | Centocor Ortho Biotech Inc. | Methods for purifying cells derived from pluripotent stem cells |
| US9752125B2 (en) | 2010-05-12 | 2017-09-05 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| PH12013500349A1 (en) | 2010-08-31 | 2022-03-30 | Janssen Biotech Inc | Differentiation of pluripotent stem cells |
| CA2809300A1 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| CN108517310B (zh) | 2010-08-31 | 2022-02-15 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| AU2012301617A1 (en) | 2011-09-02 | 2014-04-17 | Salk Institute For Biological Studies | CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity |
| KR102203056B1 (ko) | 2011-12-22 | 2021-01-14 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화 |
| KR20140131999A (ko) | 2012-03-07 | 2014-11-14 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 증폭 및 유지를 위한 한정 배지 |
| KR102667288B1 (ko) | 2012-06-08 | 2024-05-17 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화 |
| WO2014106141A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
| WO2014105546A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
| RU2768963C2 (ru) | 2012-12-31 | 2022-03-25 | Янссен Байотек, Инк. | Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| HRP20191283T1 (hr) | 2014-01-24 | 2019-10-18 | Turning Point Therapeutics, Inc. | Diaril makrocikli kao modulatori protein kinaze |
| EP3954759A1 (de) | 2014-05-16 | 2022-02-16 | Janssen Biotech, Inc. | Verwendung kleiner moleküle zur verstärkung der mafa-expression in endokrinen pankreaszellen |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| EP4397665A3 (de) | 2015-07-06 | 2024-08-21 | Turning Point Therapeutics, Inc. | Diarylmakrozykluspolymorph |
| CA3020905A1 (en) | 2016-04-14 | 2017-10-19 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells to intestinal midgut endoderm cells |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| KR102357045B1 (ko) | 2017-03-31 | 2022-01-28 | 뉴로디아그노스틱스 엘엘씨 | 알츠하이머 질환에 대한 림프구-기반 형태계측 시험 |
| WO2018231743A1 (en) * | 2017-06-12 | 2018-12-20 | Temple University-Of The Commonwealth System Of Higher Education | Protein kinase c-delta targeted therapy for treating radiation injury |
| BR112020001695A2 (pt) | 2017-07-28 | 2020-07-21 | Turning Point Therapeutics, Inc. | compostos macrocíclicos e usos dos mesmos |
| CN111511746B (zh) | 2017-12-19 | 2024-01-09 | 特普医药公司 | 用于治疗疾病的巨环化合物 |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0657458A1 (de) * | 1993-12-07 | 1995-06-14 | Eli Lilly And Company | Proteinkinase C-Inhibitoren |
| WO1997041127A1 (en) * | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Halo-substituted protein kinase c inhibitors |
| US6093713A (en) * | 1997-12-31 | 2000-07-25 | Kyowa, Hakko, Kogyo Co., Ltd. | 3'-epimeric K-252A derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5100393A (en) * | 1992-09-25 | 1994-04-26 | Schering Corporation | Diindolo compounds and pharmaceutical compositions containing them |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
-
2001
- 2001-12-06 CA CA002431187A patent/CA2431187A1/en not_active Abandoned
- 2001-12-06 ES ES01996227T patent/ES2245994T3/es not_active Expired - Lifetime
- 2001-12-06 RU RU2003120442/04A patent/RU2275373C2/ru not_active IP Right Cessation
- 2001-12-06 MX MXPA03005139A patent/MXPA03005139A/es active IP Right Grant
- 2001-12-06 US US10/008,982 patent/US6828327B2/en not_active Expired - Lifetime
- 2001-12-06 AT AT01996227T patent/ATE301661T1/de not_active IP Right Cessation
- 2001-12-06 JP JP2002547934A patent/JP2004526676A/ja active Pending
- 2001-12-06 EP EP01996227A patent/EP1345946B1/de not_active Expired - Lifetime
- 2001-12-06 DE DE60112611T patent/DE60112611T2/de not_active Expired - Lifetime
- 2001-12-06 AU AU2737102A patent/AU2737102A/xx active Pending
- 2001-12-06 AU AU2002227371A patent/AU2002227371B2/en not_active Ceased
- 2001-12-06 WO PCT/US2001/047866 patent/WO2002046197A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0657458A1 (de) * | 1993-12-07 | 1995-06-14 | Eli Lilly And Company | Proteinkinase C-Inhibitoren |
| RU2147304C1 (ru) * | 1993-12-07 | 2000-04-10 | Эли Лилли Энд Компани | Бис-индолмалеимидные макроциклические производные, способ их получения (варианты) и фармацевтическая композиция |
| WO1997041127A1 (en) * | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Halo-substituted protein kinase c inhibitors |
| US6093713A (en) * | 1997-12-31 | 2000-07-25 | Kyowa, Hakko, Kogyo Co., Ltd. | 3'-epimeric K-252A derivatives |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2518471C2 (ru) * | 2008-08-14 | 2014-06-10 | Тиботек Фармасьютикалз | Макроциклические индольные производные, применимые в качестве ингибиторов вируса гепатита с |
| RU2728579C2 (ru) * | 2015-07-21 | 2020-07-30 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы и их применение |
| RU2630958C2 (ru) * | 2015-12-29 | 2017-09-15 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) | Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1345946A1 (de) | 2003-09-24 |
| CA2431187A1 (en) | 2002-06-13 |
| MXPA03005139A (es) | 2004-01-29 |
| HK1055956A1 (en) | 2004-01-30 |
| JP2004526676A (ja) | 2004-09-02 |
| DE60112611D1 (de) | 2005-09-15 |
| US20030078280A1 (en) | 2003-04-24 |
| AU2737102A (en) | 2002-06-18 |
| WO2002046197A1 (en) | 2002-06-13 |
| AU2002227371B2 (en) | 2007-05-10 |
| ES2245994T3 (es) | 2006-02-01 |
| DE60112611T2 (de) | 2006-06-14 |
| EP1345946B1 (de) | 2005-08-10 |
| ATE301661T1 (de) | 2005-08-15 |
| US6828327B2 (en) | 2004-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2275373C2 (ru) | Макрогетероциклические соединения | |
| AU2002227371A1 (en) | Macroheterocylic compounds useful as kinase inhibitors | |
| US7705015B2 (en) | Substituted pyrroline kinase inhibitors | |
| US6987110B2 (en) | Substituted pyrrolines as kinase inhibitors | |
| EP1654255B1 (de) | Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren | |
| US20090093634A1 (en) | Substituted pyrroline kinase inhibitors | |
| CN101646673A (zh) | 作为pkc抑制剂的3-氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 | |
| HK1055956B (en) | Macroheterocylic compounds useful as kinase inhibitors | |
| US20070088019A1 (en) | Macroheterocyclic compounds as kinase inhibitors | |
| EP1900738A2 (de) | Substituierte Pyrrolinkinase-Hemmer | |
| HK1057370A1 (en) | Indazolyl-substituted pyrroline compounds as kinase inhibitors | |
| HK1057370B (en) | Indazolyl-substituted pyrroline compounds as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20191207 |